Scientists have built a molecular 'trash collector' that doesn't just block cancer—it physically deletes the protein shields tumors use to hide from our immune system.
April 15, 2026
Original Paper
Discovery and Development of First-in-Class Cereblon-Recruiting RIPK1 Degraders
bioRxiv · 10.64898/2026.04.10.717852
The Takeaway
For years, we’ve tried to fight cancer by using drugs to block the proteins that help tumors survive, but the tumors often just adapt and become resistant. This study introduces LD5095, a first-of-its-kind 'degrader' that doesn't just block a protein called RIPK1—it tricks the cell into dragging that protein to the cellular trash can and destroying it entirely. By removing RIPK1, the researchers were able to make stubborn tumors sensitive to immunotherapy again, effectively stripping away their armor. This is a massive shift from traditional medicine because it’s much harder for a tumor to build resistance to a drug that deletes its defenses instead of just clogging them. For regular people, this means we’re moving toward a future where 'untreatable' cancers can be forced out of hiding and finally killed by our own immune systems.
From the abstract
Receptor-interacting protein kinase 1 (RIPK1) is a critical regulator of programmed cell death and is implicated in various patholog-ical conditions, particularly in mediating tumor resistance to immune checkpoint inhibitors (ICBs). In this study, we have pioneered the development of a novel cereblon (CRBN)-recruiting RIPK1 degrader, LD5095 , through systematic optimization of linker and CRBN ligand portion. LD5095 demonstrates potent and selective RIPK1 degradation across cell lines, with rapid